Carpenter Technology Corporation engages in the manufacture, fabrication, and distribution of specialty metals in the United States, Europe, the Asia Pacific, Mexico, Canada, and internationally. It operates in two segments, Specialty Alloys Operations and Performance Engineered Products. The company offers specialty alloys, including titanium alloys, powder metals, stainless steels, alloy steels, and tool steels, as well as additives, and metal powders and parts. It serves to aerospace, defense, medical, transportation, energy, industrial, and consumer markets. The company was founded in 1889 and is headquartered in Philadelphia, Pennsylvania.

Carpenter Technology Corporation

In a report released today, Glynis Johnson from Jefferies reiterated a Buy rating on Crest Nicholson Holdings, with a price target of p230.00. Acco...

Jefferies Remains a Buy on Crest Nicholson Holdings (CRST)

Caprice Resources Ltd. ( ($AU:CRS) ) has provided an announcement. Caprice Resources has reported a new set of high-grade assay results from Phase ...

Caprice Extends High-Grade Gold at Island Project and Restarts Phase 4 Drilling

There’s a lot to be optimistic about in the Industrial Goods sector as 2 analysts just weighed in on Carpenter Technology (CRS – Research Report) a...

Analysts Offer Insights on Industrial Goods Companies: Carpenter Technology (CRS) and RELX plc (OtherRLXXF)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Praxis Precision Medicines (PRAX – Research Report),...

Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), Dexcom (DXCM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Crispr Therapeutics AG (CRSP – Research Report) and ...

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and NeoGenomics (NEO)

An update from Aclaris Therapeutics ( ($ACRS) ) is now available. On January 12, 2026, Aclaris Therapeutics updated its corporate overview presenta...

Aclaris Therapeutics Expands Inflammation and Immunology Pipeline Strategy

Aclaris Therapeutics ( ($ACRS) ) just unveiled an announcement. On January 6, 2026, Aclaris Therapeutics reported positive interim data from a firs...

Aclaris advances ATI-052 after positive Phase 1a results

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Crispr Therapeutics AG today and set a price target of $90.00. Accordi...

Crispr Therapeutics AG (CRSP) Gets a Buy from Bank of America Securities

Wells Fargo analyst Yanan Zhu maintained a Hold rating on Crispr Therapeutics AG today and set a price target of $75.00. Zhu covers the Healthcare ...

Wells Fargo Remains a Hold on Crispr Therapeutics AG (CRSP)

Cathie Wood’s ARK funds delivered a standout performance in 2025, handily beating the broader market. In her new year’s message , Wood described 20...

Cathie Wood’s ARK Funds Had ‘One Heck of a Year’ — Key Trends for 2026

An announcement from Mineral Road Discovery ( ($TSE:ROAD) ) is now available. Mineral Road Discovery Inc. has issued 5,000,000 units to Mineral Roa...

Mineral Road Discovery Swaps Shares for $500,000 Stake in Golcap Resources

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made just one trade on Friday, December 26, according to its daily fund disclosures. The firm...

Current Quarter	$2.2	Next Quarter	$2.52
Current Year	$10.07	Next Year	$12
QoQ Growth	+14.5%	YoY Growth	+19.2%
3Y EPS CAGR	+1.1%	Target Price	$389.67
Consensus	Buy	Upside	+16.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRS	$335.77	+0.30%	699.67K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRS	$335.77	+0.3%	699.67K
3
4
5
6

CRS

CRS

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Carpenter Technology Corporation Data in Excel

Get Carpenter Technology Corporation Data in Excel